Introduction
Technovigilance in Mexico is a critical post-market surveillance activity that ensures medical devices remain safe and effective throughout their lifecycle. For foreign manufacturers entering the Mexican market, understanding adverse incident reporting and the role of the Mexican Registration Holder (MRH) is essential for compliance with NOM-240-SSA1 and COFEPRIS requirements.
This article explains what constitutes an adverse incident, who is responsible for reporting, and the timelines and processes involved.
What Is Technovigilance in Mexico?
Technovigilance or Medical Device Surveillance refers to the systematic monitoring of medical devices after they have been placed on the market. Its goal is to detect, evaluate, and prevent risks associated with device use. In Mexico, this program is regulated by NOM-240-SSA1, which aligns with international post-market surveillance standards.
What Is an Adverse Incident?
An adverse incident is any event related to a medical device that results from a malfunction and could lead to death or significant health deterioration. Examples include:
- Unexpected device failures not identified during risk evaluation.
- Incorrect labeling or instructions causing harm.
- Interactions with other products or substances leading to adverse outcomes.
- Diagnostic errors (false positives or negatives) that compromise patient safety.
The Role of the Registration Holder
The Mexico Registration Holder (MRH) is the legal representative of the manufacturer and is primarily responsible for implementing and maintaining the technovigilance program.
Key responsibilities include:
- Coordinating incident reporting with manufacturers, distributors, and healthcare providers.
- Ensuring timely notifications to the National Center of Pharmacovigilance (CNFV) through COFEPRIS.
- Maintaining a Technovigilance Unit staffed with trained personnel familiar with NOM-240 requirements.
Manufacturers outside Mexico must maintain close communication with their MRH to ensure compliance and receive feedback on incidents occurring in Mexico or globally.
COFEPRIS Adverse Incident Reporting Process
There are two official channels for reporting:
- Hardcopy Submission: Using the official COFEPRIS format and delivering it to the Integral Services Center (CIS).
- Online Platform: Submitting notifications digitally via the COFEPRIS technovigilance portal.
Each initial notification must include:
- Sanitary Registration number
- Device identification and classification
- Description of the incident and its consequences
- Patient and operator details
- Actions taken following the event
Follow-up and final notifications are required to close the case, detailing corrective and preventive measures.
It is important to note that not every issue involving a medical device is considered reportable. Section 7.2 of NOM‑240‑SSA1 clearly outlines the criteria for determining which incidents must be reported to COFEPRIS. For a more detailed explanation of these criteria and their appropriate application, you may refer to Technovigilance for Medical Devices in Mexico which analyzes in depth when an incident should, and should not, be reported.
Technovigilance Responsibilities for Distributors and Healthcare Professionals in Mexico
In addition to the MRH and manufacturer, distributors and healthcare professionals also carry explicit responsibilities under NOM‑240-SSA1. Distributors must immediately communicate any suspected adverse incidents to the MRH and support documentation collection, device retrieval, and corrective actions. Healthcare professionals, who often detect issues first, are obligated to report incidents promptly and accurately, ensuring that early warning signals are not overlooked.
Effective technovigilance depends on strong collaboration among all parties involved: the manufacturer, MRH, distributors, and healthcare professionals. A well‑coordinated communication chain ensures timely reporting, accurate evaluation, and rapid implementation of necessary preventive or corrective measures to protect patient safety.
Adverse Incident Reporting Timelines
The MRH must adhere to strict reporting deadlines:
- Public health threat: Within 2 working days
- Death or serious health deterioration: Within 10 days
- Other adverse incidents: Within 30 days
FAQs: Mexico Technovigilance and Adverse Incident Reporting
- What is technovigilance in Mexico?
Technovigilance is the post-market surveillance program for medical devices regulated by NOM-240-SSA1. It ensures device safety through systematic monitoring and incident reporting.
- Who is responsible for reporting adverse incidents to COFEPRIS?
The Mexican Registration Holder is primarily responsible for reporting adverse incidents. However, manufacturers, distributors, healthcare professionals, patients, and any individual involved with the medical device can also file a report with COFEPRIS.
- What are the timelines for reporting adverse incidents?
- Public health threat: 2 working days
- Death or serious health deterioration: 10 days
- Other adverse incidents: 30 days
- How do you report an adverse incident to COFEPRIS?
Reports can be submitted via hardcopy using the official format or through the COFEPRIS online platform.
- Why is the Registration Holder critical for compliance?
The MRH manages the technovigilance program, ensures timely reporting, and acts as the legal representative of the manufacturer in Mexico.
Conclusion
Adverse incident reporting is not only a regulatory obligation but a vital practice to ensure patient safety and maintain market authorization in Mexico. Manufacturers should establish robust communication with their MRH and implement proactive technovigilance strategies. A strong and collaborative relationship among manufacturers, the MRH, distributors, and healthcare professionals is essential to ensure accurate reporting and rapid risk mitigation. When in doubt, authorities encourage reporting rather than withholding information.
If you need support in your Technovigilance Unit, notifications and/or reports, please contact us at [email protected]